skyla

Founded in 2011, skyla is leveraging Taiwan's IT infrastructure and engineering expertise from Taiwan's Industrial Technology Research Institute (ITRI), we specialize in innovative In Vitro Diagnostic (IVD) Point-of-Care Testing (POCT) for both human and veterinary healthcare. Our multiplexing platforms allow for quick, easy, and simultaneous biomarker monitoring from a micro-sample, providing fast and reliable results. With a professional team skilled in reagents, optics, electronics, mechanics, software, and automation, skyla delivers high-quality diagnostic solutions. Our products are FDA, CE, CFDA, TFDA, QMS certified and sold in over 92 countries, a testament to our growing impact on healthcare systems around the world. Customer-centric innovation is at our core. We are developing fully automated POCT systems, including biochemistry, immunology, coagulation, urine, PCR, and rapid test, to meet global healthcare needs. Our vision is to be a trusted partner in both human and veterinary diagnostics, always pushing the boundaries of what's possible. At skyla, we believe "The sky's the limit" as we continue to innovate for a healthier future.

• Employees 21
• Founded 2011
• Annual Revenue $7703000